(Q46703844)

24 December 2017

title

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations (English)

1 reference

24 December 2017

1 reference

3

Hagop Kantarjian

1 reference

24 December 2017

5

Francis Giles

1 reference

24 December 2017

4

Jorge Cortes

1 reference

24 December 2017

6

Maher Albitar

1 reference

24 December 2017

1

Tai-Sung Lee

1 reference

24 December 2017

author name string

Steven J Potts

series ordinal

2

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

8

1 reference

24 December 2017

page(s)

1744-1753

1 reference

24 December 2017

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Imatinib: a selective tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Structural basis for the autoinhibition of c-Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Comparison of simple potential functions for simulating liquid water

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

VMD: visual molecular dynamics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Scalable molecular dynamics with NAMD

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

A Src-like inactive conformation in the abl tyrosine kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

A smooth particle mesh Ewald method

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23355

7 January 2021

Identifiers

DOI

10.1002/CNCR.23355

1 reference

24 December 2017

1 reference

24 December 2017